FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused by Mycobacterium abscessus (Mab), a severe nontuberculous mycobacterium (NTM) infection. The research was led by Dr. Gyanu Lamichhane, Associate Professor at Johns Hopkins University School of Medicine.
The study, published in Antimicrobial Agents and Chemotherapy, evaluated MRX-5 against clinical isolates of M. abscessus in a validated mouse model. The results revealed that MRX-5 achieved a dose-dependent reduction in lung bacterial burden, with dose of 15 mg/kg showing efficacy comparable to the current standard-of-care.
Key Findings:
"We are excited about the potential of MRX-5 to provide a much-needed new treatment option for patients suffering from Mycobacterium abscessus infections," said Jerry Li, the President of MicuRx Pharmaceuticals. "The oral formulation of MRX-5 represents a critical advancement in NTM therapy, particularly for vulnerable patient populations, including those with cystic fibrosis, bronchiectasis, and immunosuppression, who struggle with existing treatment regimens."
Mab infections are notoriously difficult to treat, often requiring prolonged, complex, and poorly tolerated courses of multiple antibiotics. With no FDA-approved treatment for Mab, the results of this study are a promising step towards addressing the growing unmet clinical need for effective and convenient treatment options. Importantly, MRX-5 offers an oral alternative to current treatment regimens that are primarily intravenous and highly toxic, with failure rates exceeding 50%. MRX-5 could vastly improve patient compliance and quality of life compared to the current standard intravenous therapies.
MicuRx Pharmaceuticals is committed to advancing the development of MRX-5 and looks forward to initiating clinical trials in patients to further evaluate its safety and efficacy in human subjects.
For more information, please contact:
MicuRx Pharmaceuticals, Inc.
Email: info@micurx.com
Website: www.micurx.com
About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of multidrug-resistant infections. With a mission to address significant unmet medical needs, MicuRx is advancing a portfolio of drug candidates targeting difficult-to-treat infections.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections
DUBAI, UAE, Nov. 9, 2024 /PRNewswire/ -- Nakheel, a member of Dubai Holding's pioneering real estate arm Dubai Holding Real Estate, has marked significant progress in the development of Palm Jebel Ali in 2024, with the project progressing at pace to meet 2025 milestones.
The development masterplan was approved by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai in May 2023, who said at the time; "Palm Jebel Ali will further strengthen our urban infrastructure and consolidate the city's emergence as one of the world's leading metropolises. This new groundbreaking project reflects our strategic development plan centred on raising the quality of life and happiness of residents."
The Palm Jebel Ali area received further recognition this year when His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of The Executive Council of Dubai, approved the master plan for the 6.6 kilometre development of Jebel Ali Beach. The project includes a five-kilometre sandy beach, to be developed by Nakheel, as well as a 1.6-kilometre-long Mangrove Beach, to be developed by Dubai Municipality.
Khalid Al Malik, Chief Executive Officer of Dubai Holding Real Estate, said; "At Nakheel we believe in developing dreams, inspired by the vision of our leaders and the hopes of our people. The rapid progress we are currently witnessing on ground at Palm Jebel Ali is testimony to the grand success of our key partnerships and our joint endeavours to ensure we deliver on our commitments."
Several key contracts for the project were awarded throughout 2024, including the construction of a new 6-kilometre road, the contracts for the island's marine works, dredging, land reclamation, beach profiling and sand placement, directly supporting the construction of villas. The first eight fronds of the project are expected to be site-ready for villa infrastructure and civil works by the first quarter of 2025.
Crucially, the contract for the construction of exclusive ultra-luxury villas on the first six fronds of the project has also been awarded and are scheduled for completion by late 2026. Nakheel recently announced their partnership with Dubai Electricity and Water Authority for the development of two substations on Palm Jebel Ali.
Video: Palm Jebel Ali
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Palm Jebel Ali Project Surges Ahead in 2024: Milestones Achieved in Record Time for Dubai's Most Anticipated Development
Palm Jebel Ali Project Surges Ahead in 2024: Milestones Achieved in Record Time for Dubai's Most Anticipated Development
Palm Jebel Ali Project Surges Ahead in 2024: Milestones Achieved in Record Time for Dubai's Most Anticipated Development